Experimental drug before surgery for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called IBI363 given before surgery for early-stage non-small cell lung cancer. The goal is to see if it can help shrink the tumor and improve the chances of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage II, IIIA, or IIIB non-small cell lung cancer that can be surgically removed.
- You have not had any prior treatment for your lung cancer.
- You do not have EGFR mutations or ALK rearrangements.
- Your PD-L1 test result is 1% or higher.
- You are generally well enough to have surgery (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This Phase 2 trial tests a combination of IBI308 plus bevacizumab and pemetrexed/carboplatin given before surgery, aiming to shrink or control unresectable stage III non-small cell lung cancer. It may help some people become eligible for surgery and improve outcomes, while also testing safety and effectiveness.
Hear when a new Resectable Stage II-III Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.